About
Afripharma is a leading pharmaceutical company dedicated to meeting the healthcare needs of the community. Focusing on deworming children, we work closely with governments to implement mass deworming programs in schools and communities, targeting the most vulnerable age group – our children. Our team of experts is driven by a passion for child welfare and a vision of a mosquito-free continent.
Why Us?
Best Filming Equipment
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
10 Years of Experience
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Professional Editing
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
Our Address
1 Gibfield Park Ave Atherton Manchester M46 0SU
Company Background
• Founded by Teo van Niekerk and John Holland 2022
• Registered in England 2023
• Focused on Africa and its need for appropriately priced pharma solutions for its people
• Initial de-worming product formulated for the third sector and selected countries
Unique Sales Model
•Through decades old relationships Afripharma is able to supply and deliver pharma and nutritional products into several countries in Africa at ministerial level
•We consult with governments to create medical programs for the population and provide the products for these projects
•We are able to bring long, trusted global donor relationships to support these programs and partner with governments to ensure success
Albendazole
• Formulation devised by Afripharma for children
• Single dose formulation aimed at government programs
• Chewable product able to withstand African heat and humidity
• Sweetened for ease of administering
Manufacturing
•Afripharma has an exclusive manufacture contract with a Sahpra approved manufacturer for Wormgo
•This relationship has brought with it over 900 other products which Afripharma will have exclusive distribution rights to
•The partnership has full use of in-house laboratories for product specification sheets and rapid testing and approval of other products which are being planned for launch in 2024
Initial Targets
•We are in discussions with 4 countries designing and funding national programs
•We assume a minimum of 1 million children per country for initial de-worming doses which will be followed up in 6 months with a second dosing program
•Target pricing per dose is currently in line with World Bank bench marking standards